TheresaRyanMD

PubMed

• 14 citations
  Docetaxel, Oxaliplatin, and 5‐Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long‐Term Follo...
  Ari Rosenberg, Alfred Rademaker, Howard S. Hochster, Theresa Ryan, Thomas A. Hensing, Veena Shankaran, Lisa Baddi, Devalingam Mahalingam, Mary F. Mulcahy, Al B. Benson> ;The Oncologist. 2019 Aug 1
• 2 citations
  Can we downstage locally advanced pancreatic cancer to resectable? A phase I/II study of induction oxaliplatin and 5-FU chemoradiation
  Salvatore Amodeo, Antonio Masi, Marcovalerio Melis, Theresa Ryan, Howard S. Hochster, Deirdre Jill Cohen, Anurag Chandra, H. Leon Pachter, Elliot Newman> ;Journal of Gastrointestinal Oncology. 2018 Oct 1
• 19 citations
  Multicenter, randomized, double‐blind phase 2 trial of FOLFIRI with regorafenib or placebo as second‐line therapy for metastatic colorectal cancer
  Hanna K. Sanoff, Richard M. Goldberg, Anastasia Ivanova, Seamus O'Reilly, Samer S. Kasbari, Richard D. Kim, Ray McDermott, Dominic T. Moore, William C. Zamboni, Willia...> ;Cancer. 2018 Aug 1
• 110 citations
  Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia.
  Sarah K. Tasian, David T. Teachey, Yong Li, Feng Shen, Richard C. Harvey, I-Ming Chen, Theresa Ryan, Tiffaney Vincent, Cheryl L. Willman, Alexander E. Perl, Stephen P....> ;Blood. 2017 Jan 12
• 163 citations
  Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia.
  Shannon L. Maude, Sibasish Dolai, Cristina Delgado-Martin, Tiffaney Vincent, Alissa Robbins, Arthavan Selvanathan, Theresa Ryan, Junior Hall, Andrew C. Wood, Sarah K. ...> ;Blood. 2015 Mar 12
• 6 citations
  Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer
  Johanna C. Bendell, Heinz-Josef Lenz, Theresa Ryan, Bassel F. El-Rayes, John L. Marshall, Manuel Modiano, Lowell L. Hart, Clint D. Kingsley, Thomas J. George, Daisuke ...> ;Investigational New Drugs. 2014 Apr 3
• 34 citations
  Randomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer.
  Christopher R. Garrett, Tanios Bekaii-Saab, Theresa Ryan, George A. Fisher, Sally Clive, Petr Kavan, Einat Shacham-Shmueli, Aby Buchbinder, Richard M. Goldberg> ;Cancer. 2013 Dec 15
• 3 citations
  Cisplatin with Capecitabine: Tolerance and Activity in a Phase I/II Study Preferentially Enrolling Patients with Gastric Cancer
  Jennifer Wu, Theresa Ryan, Benjamin Levinson, Elliot Newman, Howard S. Hochster, Franco M. Muggia> ;Anticancer Research. 2012 Mar 1
• Phase II study of EZN-2208 (PEG-SN38) with or without cetuximab in patients with metastatic colorectal cancer (CRC).
  Goldberg RM, Garrett CR, Berkowitz NC, Bekaii-Saab TS, Ryan T, Fisher GA, Clive S, Kavan P, Shmueli E, Buchbinder A> ;J. Clin. Oncol.. 2012-02-01
• 3 citations
  Postoperative Intraperitoneal 5-Fluoro-2′-Deoxyuridine Added to Chemoradiation in Patients Curatively Resected (R0) for Locally Advanced Gastric and Gastroesophageal J...
  Deirdre Jill Cohen, Elliot Newman, Syma Iqbal, Richard Y. Chang, Milan Potmesil, Theresa Ryan, Bernadine Donahue, Anurag Chandra, Mengling Liu, Minerva Utate, Spiros P...> ;Annals of Surgical Oncology. 2012 Feb 1
• Phase II study of sorafenib with gemcitabine and erlotinib (GES) in first-line advanced pancreatic cancer.
  Cohen DJ, Leichman LP, Love E, Ryan T, Leichman CG, Newman E, Levinson B, Hochster HS> ;J. Clin. Oncol.. 2011-02-01
• 33 citations
  Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma
  Jennifer Wu, Charles A. Henderson, Lynn G. Feun, Peter J. Van Veldhuizen, Philip J. Gold, Hui Zheng, Theresa Ryan, Lawrence S. Blaszkowsky, Haobin Chen, Max Costa, Bar...> ;Investigational New Drugs. 2010 Oct 1
• Activity and tolerance of biweekly CapeOx-cetuximab in 1st line therapy of metastatic colorectal cancer (mCRC): Relation to K-ras mutation status.
  Yuan Y, Ma H, Cohen DJ, Ryan T, Choi H, Love' E, Awad M, Khambata-Ford S, Mauro D, Hochster H> ;J. Clin. Oncol.. 2009-05-20
• Safety and tolerability of combined gemcitabine (G) and erlotinib (E) plus sorafenib (S) in the first-line treatment of metastatic pancreatic cancer.
  Cohen DJ, Ryan T, Moskovits T, Cazeau N, Newman E, Pachter HL, Hochster HS> ;J. Clin. Oncol.. 2009-05-20
• Neoadjuvant therapy of gastric cancer with cetuximab added to both irinotecan and cisplatin, followed by surgical resection and adjuvant chemoradiation.
  Ma HY, Newman E, Ryan T, Miller G, Sarpel U, Pachter HL, Cohen DJ, Choi H, Goldberg JD, Hochster HS> ;J. Clin. Oncol.. 2009-05-20
• 213 citations
  Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized P...
  Howard S. Hochster, Edie Weller, Randy D. Gascoyne, Thomas M. Habermann, Leo I. Gordon, Theresa Ryan, Lijun Zhang, Natalia Colocci, Stanley Frankel, Sandra J. Horning> ;Journal of Clinical Oncology. 2009 Apr 1
• 33 citations
  Phase I/II Trial of Induction Chemotherapy Followed by Concurrent Chemoradiotherapy and Surgery for Locoregionally Advanced Pancreatic Cancer
  Jennifer L. Marti, Howard S. Hochster, Spiros P. Hiotis, Bernadine Donahue, Theresa Ryan, Elliot Newman> ;Annals of Surgical Oncology. 2008 Oct 2
• 91 citations
  mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia.
  David T. Teachey, Cecilia Sheen, Junior Hall, Theresa Ryan, Valerie I. Brown, Jonathan D. Fish, Gregor S. D. Reid, Alix E. Seif, Robin Norris, Yueh J. Chang, Martin Ca...> ;Blood. 2008 Sep 1
• A phase I/II study to determine the feasibility and efficacy of the triple combination of oblimersen (OBL), abraxane (ABX), and temozolomide (TMZ) in metastatic melano...
  Pavlick AC, Escalon J, Madden K, Yepes E, Staha J, Ryan T, Buckley MT, Mendoza S, Yee H, Liebes LF> ;J. Clin. Oncol.. 2008-05-20
• Phase I dose-escalating study of bi-weekly pemetrexed (MTA) with fixed dose rate gemcitabine (gem) in patients with advanced cancer.
  Chen AL, Ryan T, Muggia F, Chachoua A, Escalon J, Moore S, Haniff F, Levinson B, Nicol S, Hochster H> ;J. Clin. Oncol.. 2006-06-20
• 17 citations
  Neoadjuvant chemotherapy, surgery, and adjuvant intraperitoneal chemotherapy in patients with locally advanced gastric or gastroesophageal junction carcinoma : A phase...
  Elliot Newman, Milan Potmesil, Theresa Ryan, Stuart G. Marcus, Spiros P. Hiotis, Herman Yee, Brendan Norwood, Marc Wendell, Franco M. Muggia, Howard S. Hochster> ;Seminars in Oncology. 2005 Dec 1
• Postoperative intraperitoneal (IP) 5'-fluoro-2'-deoxyuridine (FUDR) added to chemoradiation in patients curatively resected (R0) for locally advanced gastric and gastr...
  Newman E, Chang RY, Potmesil M, Donahue B, Marcus SG, Hiotis SP, Iqbal S, Ryan T, Hochster HS, Muggia FM> ;J. Clin. Oncol.. 2005-06-01
• Prognostic significance of the follicular lymphoma international prognostic index (FLIPI) in the E1496 trial of chemotherapy with or without maintenance rituximab.
  Colocci N, Weller E, Hochster HS, Gascoyne R, Kumm B, Ryan T, Habermann TM, Frankel SR, Horning SJ> ;J. Clin. Oncol.. 2005-06-01
• Results of a phase I study of fixed dose rate gemcitabine /irinotecan (FIGI).
  Ryan T, Hochster H, Escalon J, Muggia FM> ;J. Clin. Oncol.. 2004-07-15
• Results of E1496: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL).
  Hochster HS, Weller E, Ryan T, Habermann TM, Gascoyne R, Frankel SR, Horning SJ> ;J. Clin. Oncol.. 2004-07-15
• Join now to see all